Glucotrack, Inc. 8K

Lokahi Therapeutics filed reviewed interim financials with a going-concern warning, significant short-term secured debt and related-party settlement-driven ownership realignment, and disclosed a pending reverse-merger with Glucotrack, Inc. that will give Lokahi holders 90% of the combined company.

Lokahi Therapeutics, Inc., a development-stage biopharmaceutical subsidiary of Apimeds Pharmaceuticals US, Inc., filed an 8-K that includes reviewed standalone interim financial statements as of and for the six months ended June 30, 2026, accompanied by an independent accountants’ review report that highlights substantial doubt about the company’s ability to continue as a going concern due to recurring losses, negative operating cash flows, and minimal cash on hand. The filing discloses significant related-party and third-party debt financings in 2026, including $5 million of secured promissory notes to the Keren Eliyahu Charitable Trust with an aggregate repayment obligation of $6.1 million due by September 30, 2026, and the assumption of $500,100 of related-party notes under an April 24, 2026 settlement agreement among Lokahi, its parent APUS, Inscobee, Apimeds Korea, and others, under which Lokahi contributed $3 million of working capital and forgave intercompany advances in exchange for assignment of Apitox program rights and a CRO credit facility, and a post-settlement equity realignment under which APUS must distribute 51% of Lokahi’s common stock as directed by CEO Erik Emerson. The notes describe an August 2026 potential legal exposure arising from Alto Opportunity Master Fund B’s indication that it may pursue litigation against APUS, Lokahi and certain officers/directors related to a $10.9 million APUS note (for which Lokahi currently records no liability). Subsequent events disclose that on July 14, 2026 Glucotrack, Inc. entered into a merger agreement whereby all Lokahi common stock will be converted into Glucotrack common and Series A preferred stock such that former Lokahi holders own 90% of Glucotrack’s fully diluted equity post-closing, and that APUS has executed an acknowledgment of transfer and beneficial ownership agreement releasing 51% of its Lokahi stake in line with the earlier settlement.

Filing Facts

CIK

1506983

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-040600

Alert Tier

8